1700090G07Rik Inhibitors
The chemical class of 1700090G07Rik inhibitors comprises a diverse array of compounds targeting key signaling pathways involved in cellular processes associated with 1700090G07Rik. These inhibitors act on various molecular targets, including kinases and receptors, to modulate signaling cascades crucial for cellular function.
The inhibitors presented, such as rapamycin, LY294002, and U0126, exert their effects through mTOR, PI3K/Akt, and MAPK/ERK pathways, respectively. These pathways play essential roles in cell survival, growth, and proliferation, and their inhibition can impact the regulation of 1700090G07Rik-related processes. Other inhibitors like Wortmannin, SB203580, and SP600125 target PI3K, p38 MAPK, and JNK pathways, respectively, influencing cellular responses linked to 1700090G07Rik
SEE ALSO...
Items 11 to 12 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SB-216763 | 280744-09-4 | sc-200646 sc-200646A | 1 mg 5 mg | $71.00 $202.00 | 18 | |
SB216763 is a selective inhibitor of GSK-3 (glycogen synthase kinase-3), influencing the Wnt/β-catenin signaling pathway. Inhibition of GSK-3 by SB216763 may modulate cellular processes linked to 1700090G07Rik, as Wnt/β-catenin signaling regulates cell fate and proliferation. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a selective inhibitor of MEK1/2, impacting the MAPK/ERK signaling pathway. Inhibition of MEK1/2 by selumetinib can influence pathways associated with 1700090G07Rik, as the MAPK/ERK pathway regulates cell proliferation and differentiation. | ||||||